Abstract
Prostate cancer is the most frequently diagnosed disease in American men today and the second leading cause of death among them. Transformation and progression towards malignancy in prostate cancer is dependant on the inability of the prostatic epithelial cells to undergo apoptosis rather than on the regulation of proliferation. Molecular targeting of inadequacies in this process of suppression of apoptosis could prove to be of great therapeutic importance for prostate cancer patients. Existence of tissue specific promoters to aid in the delivery of genes with therapeutic potential makes molecular therapy an attractive option. This review discusses salient features of molecules such as, Bcl-2, Bcl-XL, NF-kB, Akt, PTEN and Par-4 that play a significant role in the regulation of prostate cancer and focuses on the prospects of effectively utilizing their potential for the therapy of hormone-sensitive and hormone-resistant prostate cancer.
Keywords: par-4, prostate cancer, genes, apoptosis, molecular therapy
Current Pharmaceutical Design
Title: Molecular Therapy Intervention Prospects in Prostate Cancer
Volume: 10 Issue: 5
Author(s): Yashraj D. Rege and Vivek M. Rangnekar
Affiliation:
Keywords: par-4, prostate cancer, genes, apoptosis, molecular therapy
Abstract: Prostate cancer is the most frequently diagnosed disease in American men today and the second leading cause of death among them. Transformation and progression towards malignancy in prostate cancer is dependant on the inability of the prostatic epithelial cells to undergo apoptosis rather than on the regulation of proliferation. Molecular targeting of inadequacies in this process of suppression of apoptosis could prove to be of great therapeutic importance for prostate cancer patients. Existence of tissue specific promoters to aid in the delivery of genes with therapeutic potential makes molecular therapy an attractive option. This review discusses salient features of molecules such as, Bcl-2, Bcl-XL, NF-kB, Akt, PTEN and Par-4 that play a significant role in the regulation of prostate cancer and focuses on the prospects of effectively utilizing their potential for the therapy of hormone-sensitive and hormone-resistant prostate cancer.
Export Options
About this article
Cite this article as:
Rege D. Yashraj and Rangnekar M. Vivek, Molecular Therapy Intervention Prospects in Prostate Cancer, Current Pharmaceutical Design 2004; 10 (5) . https://dx.doi.org/10.2174/1381612043453234
DOI https://dx.doi.org/10.2174/1381612043453234 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry Resisting the Resistance in Cancer: Cheminformatics Studies on Short- Path Base Excision Repair Pathway Antagonists Using Supervised Learning Approaches
Combinatorial Chemistry & High Throughput Screening Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases
Protein & Peptide Letters β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design
Letters in Drug Design & Discovery Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA)
Current Genomics Past and Present of Imaging Modalities Used for Prostate Cancer Diagnosis: Androgen Receptor Targeted Imaging of Prostate Cancer as a Future Modality for Early, Rapid and Efficient Diagnosis
Current Medical Imaging Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Current Medicinal Chemistry A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Potential Clinical Applications of (-), (+) and (±)-Z-Bisdehydrodoisynolic Acids in Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Identification of Novel Small-Molecule ASGP-R Ligands
Current Drug Delivery mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy